Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
NU E Power Corp. Announces Closing of Non-Brokered Private Placement for $1.7 Million. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Immatics NV IMTX

Healthcare Biotechnology
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell... see more

Recent & Breaking News (NDAQ:IMTX)

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

GlobeNewswire December 11, 2025

Immatics Announces $125 Million Underwritten Offering

GlobeNewswire December 5, 2025

Immatics Announces Third Quarter 2025 Financial Results and Business Update

GlobeNewswire November 17, 2025

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps  

GlobeNewswire November 12, 2025

Immatics Appoints Amie Krause as Chief People Officer

GlobeNewswire October 27, 2025

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium

GlobeNewswire October 20, 2025

Immatics Appoints Venkat Ramanan as Chief Financial Officer

GlobeNewswire October 1, 2025

Immatics Announces Second Quarter 2025 Financial Results and Business Update

GlobeNewswire August 13, 2025

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

GlobeNewswire May 31, 2025

Immatics Announces First Quarter 2025 Financial Results and Business Update

GlobeNewswire May 13, 2025

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

GlobeNewswire April 23, 2025

Immatics Announces Full Year 2024 Financial Results and Business Update

GlobeNewswire March 27, 2025

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

GlobeNewswire November 18, 2024

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

GlobeNewswire November 8, 2024

Immatics Announces Pricing of $150 Million Public Offering

GlobeNewswire October 10, 2024

Immatics Announces Proposed $150 Million Public Offering

GlobeNewswire October 10, 2024

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

GlobeNewswire October 10, 2024

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

GlobeNewswire October 4, 2024

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

GlobeNewswire September 16, 2024

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

GlobeNewswire September 6, 2024

Podcasts